Many clinical trials of mRNA-based drugs or vaccines have failed to successfully pass Phase I or Phase II. The reasons behind this are various, including low efficacy of candidate drugs and lower-than-expected clinical risk/treatment benefit profiles. Preclinical safety assessments aim to identify well-tolerated and efficacious LNP-mRNA formulations, and when toxicity is...
English
Arabic
Français
Español
Português
Deutsch
Türkçe
Dutch
Russian
Romaian
Portuguese (Brazil)
Greek